What is Crescent Biopharma, Inc.'s (CBIO) StockRank?

MoatMap's StockRank for Crescent Biopharma, Inc. (CBIO) is 37/100, with a Hold signal. This is a composite score combining Quality (37), Value (26), and Momentum (65) factor ranks across MoatMap's 20,000+ stock universe.

Does Crescent Biopharma, Inc. have an economic moat?

Crescent Biopharma, Inc. (CBIO) has a Quality factor score of 37/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Crescent Biopharma, Inc. a buy, hold, or sell?

MoatMap's current signal for Crescent Biopharma, Inc. (CBIO) is Hold, based on a StockRank of 37/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Crescent Biopharma, Inc. in?

Crescent Biopharma, Inc. (CBIO) operates in the Healthcare sector, specifically the Biotechnology industry (United States).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

CBIO

HOLDREMOVE

Crescent Biopharma, Inc. · Healthcare · United States · $499M · Avg Vol: $4M/d

StockRank

P/E (TTM)

—

ROE

—

D/E

0.0x

Dividend %

—

Director Trades · 180d

−$1.2M →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

Crescent Biopharma is a highly speculative, early-stage biotech firm with no commercialized products or cash flows, failing our fundamental quality and margin of safety screens.

COMPANY DESCRIPTION

Crescent Biopharma, Inc. is a biopharmaceutical company focused on developing innovative therapies for unmet medical needs. While specific product details may vary, the company typically leverages scientific advancements to address serious diseases through novel drug discovery and development. Crescent Biopharma aims to carve out a niche in specific therapeutic areas by bringing differentiated treatments to market, contributing to the broader healthcare landscape.

FINANCIAL SUMMARY (USD)

Year	2025
Revenue	10.8M
EPS	-12.81
Shares	30.4M
Debt	1.6M
Equity	203.0M
Op CF	-71.5M
Inv CF	-72.9M
Fin CF	323.0M

PRICE (1Y)-6.0%

SMA 50SMA 200

$17.36

RSI (14)

44.5

52W High

$27.41

From 52W High

0.6%

SCORE BREAKDOWN

Quality

ROIC

-73.3%8.3

ROE

—N/A

GP/Assets

4.9%18.4

Op. Margin

-2380.1%4.8

FCF/Assets

—N/A

Piotroski

239.0

Int. Cover

-50.0x6.1

D/E Ratio

0.01x89.8

Current Ratio

13.78x91.7

Value

P/E (TTM)

—N/A

EV/EBITDA

—N/A

P/FCF

—N/A

P/B

3.4x38.5

P/S

42.2x11.1

Div Yield

—N/A

Momentum

52W High %

63%45.9

RS 6M

38%90.7

SMA 50/200

1.38x96.1

EPS Rev 4W

0.0%49.3

EPS Rev 12W

+17.7%74.6

EPS Improve

+50%53.5

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$499M

P/E (Forward)

-6.2x

Gross Margin

100.0%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of CBIO are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
CBIO	Crescent Biopharma, Inc.(you)	$499M	37	HOLD
NGNE	Neurogene Inc.	$506M	37	HOLD
MNPR	Monopar Therapeutics Inc.	$451M	38	HOLD
BNTC	Benitec Biopharma Inc.	$421M	36	HOLD
STTK	Shattuck Labs, Inc.	$491M	33	SELL
FDMT	4D Molecular Therapeutics, Inc.	$533M	40	HOLD
ARTV	Artiva Biotherapeutics, Inc.	$474M	33	SELL
CTNM	Contineum Therapeutics, Inc.	$445M	40	HOLD
OVID	Ovid Therapeutics Inc.	$434M	42	HOLD
FTH	Faeth Therapeutics, Inc.	$512M	44	HOLD

Peer medians: ROE -22.1% · P/E 25.1x · Gross margin 44.2%

Crescent Biopharma, Inc. (CBIO) — Stock Score Summary

Crescent Biopharma, Inc. (CBIO) has a MoatMap StockRank of 37/100 based on Quality (37/100), Value (26/100), and Momentum (65/100) factor scores. The current signal is HOLD. Crescent Biopharma is a highly speculative, early-stage biotech firm with no commercialized products or cash flows, failing our fundamental quality and margin of safety screens.

Key Financial Metrics

Price	$17.36
Market Cap	$499M
P/E (Forward)	-6.19
Price/Book	3.36
Return on Invested Capital	-73.3%
Debt/Equity	0.84
Gross Margin	100.0%
Operating Margin	-2380.1%

Crescent Biopharma, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Crescent Biopharma, Inc.’s (CBIO) StockRank?: MoatMap’s StockRank for Crescent Biopharma, Inc. (CBIO) is 37/100, with a Hold signal. It is a composite of Quality (37), Value (26), and Momentum (65) factor ranks across MoatMap’s 20,000+ stock universe.
Does Crescent Biopharma, Inc. have an economic moat?: Crescent Biopharma, Inc. (CBIO) has a Quality factor score of 37/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Crescent Biopharma, Inc. a buy, hold, or sell?: MoatMap’s current signal for Crescent Biopharma, Inc. (CBIO) is Hold, based on a StockRank of 37/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Crescent Biopharma, Inc. in?: Crescent Biopharma, Inc. (CBIO) operates in the Healthcare sector, specifically the Biotechnology industry (United States).